304 related articles for article (PubMed ID: 15290738)
1. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims.
Riedel AA; Nelson M; Joseph-Ridge N; Wallace K; MacDonald P; Becker M
J Rheumatol; 2004 Aug; 31(8):1575-81. PubMed ID: 15290738
[TBL] [Abstract][Full Text] [Related]
2. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
Halpern R; Mody RR; Fuldeore MJ; Patel PA; Mikuls TR
Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724
[TBL] [Abstract][Full Text] [Related]
3. Serum urate levels and gout flares: analysis from managed care data.
Sarawate CA; Patel PA; Schumacher HR; Yang W; Brewer KK; Bakst AW
J Clin Rheumatol; 2006 Apr; 12(2):61-5. PubMed ID: 16601538
[TBL] [Abstract][Full Text] [Related]
4. Relationship between physician specialty and allopurinol prescribing patterns: a study of patients with gout in managed care settings.
Pandya BJ; Riedel AA; Swindle JP; Becker LK; Hariri A; Dabbous O; Krishnan E
Curr Med Res Opin; 2011 Apr; 27(4):737-44. PubMed ID: 21271794
[TBL] [Abstract][Full Text] [Related]
5. Gout medication treatment patterns and adherence to standards of care from a managed care perspective.
Sarawate CA; Brewer KK; Yang W; Patel PA; Schumacher HR; Saag KG; Bakst AW
Mayo Clin Proc; 2006 Jul; 81(7):925-34. PubMed ID: 16835972
[TBL] [Abstract][Full Text] [Related]
6. Rates of adherence and persistence with allopurinol therapy among gout patients in Israel.
Zandman-Goddard G; Amital H; Shamrayevsky N; Raz R; Shalev V; Chodick G
Rheumatology (Oxford); 2013 Jun; 52(6):1126-31. PubMed ID: 23392592
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with recurrent hospital admissions for gout: a case-control study.
Hutton I; Gamble G; Gow P; Dalbeth N
J Clin Rheumatol; 2009 Sep; 15(6):271-4. PubMed ID: 19734730
[TBL] [Abstract][Full Text] [Related]
8. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
Perez-Ruiz F; Calabozo M; Pijoan JI; Herrero-Beites AM; Ruibal A
Arthritis Rheum; 2002 Aug; 47(4):356-60. PubMed ID: 12209479
[TBL] [Abstract][Full Text] [Related]
9. Adherence and persistence to urate-lowering therapies in the Irish setting.
McGowan B; Bennett K; Silke C; Whelan B
Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
[TBL] [Abstract][Full Text] [Related]
10. Gout, allopurinol use, and heart failure outcomes.
Thanassoulis G; Brophy JM; Richard H; Pilote L
Arch Intern Med; 2010 Aug; 170(15):1358-64. PubMed ID: 20696962
[TBL] [Abstract][Full Text] [Related]
11. Frequency of serum creatinine monitoring during allopurinol therapy in ambulatory patients.
Raebel MA; McClure DL; Simon SR; Chan KA; Feldstein AC; Gunter MJ; Lafata JE; Harrold L; Nelson WW; Platt R
Ann Pharmacother; 2006 Mar; 40(3):386-91. PubMed ID: 16478808
[TBL] [Abstract][Full Text] [Related]
12. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population.
Wallace KL; Riedel AA; Joseph-Ridge N; Wortmann R
J Rheumatol; 2004 Aug; 31(8):1582-7. PubMed ID: 15290739
[TBL] [Abstract][Full Text] [Related]
13. The effect of serum urate on gout flares and their associated costs: an administrative claims analysis.
Halpern R; Fuldeore MJ; Mody RR; Patel PA; Mikuls TR
J Clin Rheumatol; 2009 Feb; 15(1):3-7. PubMed ID: 19125135
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.
Singh JA; Akhras KS; Shiozawa A
Arthritis Res Ther; 2015 May; 17(1):120. PubMed ID: 25963969
[TBL] [Abstract][Full Text] [Related]
15. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study.
Neogi T; Hunter DJ; Chaisson CE; Allensworth-Davies D; Zhang Y
J Rheumatol; 2006 Jan; 33(1):104-9. PubMed ID: 16267879
[TBL] [Abstract][Full Text] [Related]
16. Subjective sensation of heaviness in gout patients.
Toda K
Hiroshima J Med Sci; 2000 Jun; 49(2):101-3. PubMed ID: 10920575
[TBL] [Abstract][Full Text] [Related]
17. Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study.
Perez-Ruiz F; Atxotegi J; Hernando I; Calabozo M; Nolla JM
Arthritis Rheum; 2006 Oct; 55(5):786-90. PubMed ID: 17013833
[TBL] [Abstract][Full Text] [Related]
18. Withdrawal of longterm antihyperuricemic therapy in tophaceous gout.
van Lieshout-Zuidema MF; Breedveld FC
J Rheumatol; 1993 Aug; 20(8):1383-5. PubMed ID: 8230024
[TBL] [Abstract][Full Text] [Related]
19. Opportunities for improving medication use and monitoring in gout.
Singh JA; Hodges JS; Asch SM
Ann Rheum Dis; 2009 Aug; 68(8):1265-70. PubMed ID: 18701554
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with acute gout attacks in normouricaemic gout patients receiving allopurinol: a retrospective study.
So MW; Lee SG; Kim YG; Lee CK; Yoo B
Scand J Rheumatol; 2011 Nov; 40(6):444-7. PubMed ID: 21916803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
